Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Read more about Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Read more about Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk.
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Read more about Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
LGR5 is associated with tumor aggressiveness in papillary thyroid cancer. Read more about LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Approaches to isolation and molecular characterization of disseminated tumor cells. Read more about Approaches to isolation and molecular characterization of disseminated tumor cells.
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Read more about EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Read more about Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Read more about Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
Unexpected insights for anti-EGFR cancer therapy. Read more about Unexpected insights for anti-EGFR cancer therapy.
